Favipiravir has been approved by many countries to treat COVID-19 patients. (Photo: internet)

Under the direction of the President of the Vietnam Academy of Science and Technology, the Institute of Chemistry embarked on research and synthesis of drugs in SARS-CoV-2 treatment. Scientists have successfully studied a new and effective method of synthesizing the drug Favipiravir in the laboratory.

The research team shortened the drug synthesis process, through only three steps as opposed to seven or eight required, using materials available in the country, said Prof. Dr. Nguyen Van Tuyen, Director of the Institute.

The scientists will continue to perfect and scale up this drug synthesis process, said Tuyen.

Favipiravir is an anti-influenza drug first developed by Japan in 2014 under the name of Avigan. It works by inhibiting a viral enzyme called RNA polymerase, which prevents viral replication in human cells. This enzyme is common to several viruses, including SARS-CoV-2 which causes COVID-19.

Source: VOV

Vietnam rules out Hydroxychloroquine, uses convalescent plasma in COVID-19 treatment

Vietnam has completely halted the use of Hydroxychloroquine, the controversial antimalaria drug touted by US President Donald Trump, in its treatment of COVID-19 patients and instead opted for plasma from recovered cases.

Vietnam successfully develops two sets of SARS-CoV-2 test kits

The two test kits' development was based on the technological process of the US Centers for Disease Control and Prevention (US CDC), approved by the FDA (US Food and Drug Administration) in March.